These innovative agents represent a significant advancement in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://umarveil007484.blogtov.com/19747953/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide